Neu Health funding news – London-based Neu Health Raises €1.9 Million in Funding

Caroline Cake, CEO of Neu Health, shared: “Our goal is to change what’s possible in neurology care. Our partnership with Cedars-Sinai and OSE shows the growing global commitment to improving care for Parkinson’s disease and dementia. Together, we’re building a future where technology helps patients, care givers and doctors manage these challenging conditions.”

Neu Health’s platform is built on over 10 years of research and clinical validation from Oxford experts. It uses AI to analyze patient data and provide doctors with useful insights.

Read also - Wingbits Funding News- Sweden- based Wingbits Raises €5.3Mn to Transform Flight Tracking

The system connects a patient app with a care team dashboard, tracking symptoms, cognitive function, and mental health in clear, measurable ways.

Dr John Glaser, Chairman of the Board at Neu Health, said: “Neurological disease has claimed my father and my brother. The Neu Health technology will enable clinicians, patients and family caregivers to take major steps forward in managing these diseases. I am delighted to see the resources and talents of Cedars-Sinai, Oxford Science Enterprises and Neu Health brought to bear to materially advance the management of the health and healthcare of families like mine.”

Neu Health secured this funding after joining Cedars-Sinai’s 10th Accelerator program, which connected it with a top US healthcare institution.

As part of its growth, Neu Health will test its digital neurology platform at Cedars-Sinai. In a six-month trial, 150 patients will use the app, helping the company gather important clinical data and improve its approach for the US market.

Shlomo Melmed, MB, ChB, executive vice president of Medicine and Health Sciences and dean of the Medical Faculty at Cedars-Sinai said, “The research produced at Oxford is of the highest calibre, An ongoing relationship with Oxford Science Enterprises will serve our patients and also strengthen the academic and clinical missions of Cedars-Sinai.”

This is the first investment under a new partnership between Oxford Science Enterprises and Cedars-Sinai Intellectual Property Company. The partnership aims to support Oxford-based health-tech startups by co-building and co-investing in them.

The collaboration will help early-stage companies enter the US market faster by providing key commercial and clinical insights and allowing real-world testing of their healthcare technologies.

Heather Roxborough, PhD, senior partner of Health Tech at Oxford Science Enterprises, highlighted the strategic importance of this investment, saying, “We are excited to strengthen our relationship with Cedars-Sinai, a leading US health system, given our shared commitment to commercialising world-leading research and building innovative businesses. This partnership plays a critical role in accelerating US market entry for our companies by providing access to invaluable commercial and clinical insights and the opportunity to test our healthcare technologies live in the US market.”

About Neu Health

Neu Health is expanding its platform, and the new funding and pilot program at Cedars-Sinai are key steps in becoming a leader in digital neurology care.

The company makes advanced Parkinson's and dementia care accessible through a smartphone-based clinical platform. A spinout from the University of Oxford, Neu Health is built on 10 years of research and clinical validation.